Tuesday, 20 Aug 2019

You are here

Autoimmunity in the Setting of Primary Immunodeficiency

There are many avenues for interdisciplinary collaboration within rheumatology, as our specialty encompasses every organ system and diseases with protean manifestations. The intersection of rheumatology and immunology is well known and has become increasingly important, given the association of autoimmune conditions with many of the primary immunodeficiency syndromes. This intersection was highlighted today at ACR by two excellent abstracts.

The first was presented during the plenary session and was the result of a multi-center collaboration – Screening of patients with adult-onset idiopathic polyarteritis nodosa for deficiency of adenosine deaminiase 2 (DADA2) (abstract #2790). DADA2 is a rare genetic disorder associated with inflammation in various tissues, including vasculitis and risk of stroke.  In particular it is known to be associated with polyarteritis nodosa (PAN). The investigators of this study looked at the prevalence of DADA2 in patients with presumed idiopathic PAN. 117 patients with idiopathic PAN (all negative for hepatitis B) were screened for mutations in ADA2 and 6.8% had rare missence variants in ADA2. While there were no clinical differences between PAN patients with or without these mutations, this may have implications in screening family members as well as for treatment, as TNF inhibitors are often used to treat DAD2, but are not often used for PAN.

The second abstract (#2838), presented by Kevin Byram, was a study examining what are the most common primary immunodeficiency (PID) syndromes associated with vasculitis. They did this by querying the USIDNET, a national consortium of PID patients, for vasculitis cases. 76 patients with vasculitis (out of 4,888 PID cases) were identified. The most common PID associations were common variable immunodeficiency (38%) and Wiskott-Aldrich Syndrome (26%). Interestingly, CNS vasculitis was the most common specific vasculitis syndrome identified (14%), and vasculitis cases were reported to be present before or at the time of PID diagnosis ~50% of the time. While vasculitis is an uncommon complication of PID, it is important for rheumatologists to be aware of this entity.

 

 

 

Add new comment

More Like This

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.